From the Department of Pathology and the § Department of Genetics, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Connecticut 06536
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Survivin is a new IAP apoptosis inhibitor expressed during development and in human cancer in vivo. The coding strand of the survivin gene was extensively complementary to that of effector cell protease receptor-1 (EPR-1), prompting the present investigation on the origin and functional relationship of these two transcripts. Southern blots of genomic DNA were consistent with the presence of multiple, evolutionarily conserved, EPR-1/Survivin-related genes. By pulsed field gel electrophoresis and single- and two-color fluorescence in situ hybridization, these were contained within a contiguous physical interval of 75-130 kilobases (kb) on chromosome 17q25. In Northern blots, a single strand-specific probe identified a 1.3-kb EPR-1 mRNA broadly distributed in normal adult and fetal tissues, structurally distinct from the 1.9-kb Survivin transcript expressed in transformed cell lines. Transient co-transfection of an EPR-1 cDNA potentially acting as a Survivin antisense with a lacZ reporter plasmid resulted in loss of viability of HeLa cells. In contrast, co-transfection of an antisense cDNA of intercellular adhesion molecule-1 or a sense-oriented Survivin cDNA was without effect. In stably transfected HeLa cells, ZnSO4 induction of an EPR-1 mRNA under the control of a metallothionein promoter suppressed the expression of endogenous survivin. This resulted in (i) increased apoptosis as detected by analysis of DNA content and in situ internucleosomal DNA fragmentation and (ii) inhibition of cell proliferation as compared with induced vector control transfectants. These findings suggest the existence of a potential EPR-1/survivin gene cluster and identify survivin as a new target for disrupting cell viability pathways in cancer.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Regulated inhibition of programmed cell death (apoptosis)
preserves normal homeostasis and tissue and organ morphogenesis (1, 2).
Aberrations of this process participate in human diseases and may
contribute to cancer by abnormally prolonging cell viability with
accumulation of transforming mutations (3). Recently, several apoptosis
inhibitors related to the baculovirus iap gene have been
identified in mouse, Drosophila, and human (4). Intercalated
in TNF receptor signaling (5, 6) and NF-B-dependent
survival (7), IAP proteins contain two/three Cys/His baculovirus IAP
repeats plus a carboxyl terminus RING finger and are thought to block
an evolutionarily conserved step in apoptosis (6, 8-10). At least in
the case of XIAP (8), this may involve direct inhibition of the
terminal effector caspases
3 and
7 (11).
A novel member of the IAP gene family, designated Survivin (12), was recently identified by hybridization screening of human genomic libraries with the cDNA of a factor Xa receptor, effector cell protease receptor-1 (EPR-1) (13).1 Unlike all other IAP proteins (4), Survivin contained a single baculovirus IAP repeat and no RING finger and was selectively expressed during development and in all the most common human cancers but not in normal adult tissues in vivo (12). Intriguingly, the Survivin coding strand was extensively complementary to that of EPR-1, thus suggesting a potential functional interaction between these two transcripts (12).
In this study, we sought to dissect the molecular relationship between EPR-1 and Survivin (12, 13) and its role in apoptosis inhibition. We found that EPR-1 and Survivin are encoded by structurally and topographically distinct messages potentially originating from a gene cluster at 17q25. Secondly, down-regulation of Survivin by forced expression of EPR-1 increased apoptosis and inhibited growth of transformed cells.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cells and Cell Cultures-- Peripheral blood mononuclear cells were isolated from heparinized blood collected from normal informed volunteers by differential centrifugation on Ficoll-Hypaque (Amersham Pharmacia Biotech) at 400 × g for 22 °C and washed in phosphate-buffered saline, pH 7.4. The epithelial carcinoma HeLa cell line was obtained from American Type Culture Collection (Rockville, MD) and maintained in culture in complete growth medium (BioWhittaker, Walkersville, MD) supplemented with 10% fetal bovine serum (BioWhittaker) and 2 mM L-glutamine, according to the manufacturer's specifications.
Chromosomal Location of an EPR-1/Survivin Locus-- For fluorescence in situ hybridization, purified DNA from a Survivin P1 genomic clone (12) was labeled with digoxigenin dUTP (Amersham Pharmacia Biotech) by nick translation, combined with sheared human DNA, and hybridized to normal metaphase chromosomes derived from phytohemagglutinin-stimulated peripheral blood mononuclear cells in 50% formamide, 10% dextran sulfate, and 2× SSC. For two-color staining, biotin-conjugated probe D17Z1, specific for the centromere of chromosome 17, was co-hybridized with the digoxigenin-labeled P1 clone. Specific chromosomal staining was detected by fluoresceinated anti-digoxigenin antibodies and Texas red avidin. Slides were counterstained with propidium iodide or DAPI for one- or two-color labeling, respectively. A total of 80 metaphase cells were analyzed with 69 cells exhibiting specific labeling.
Southern Hybridization-- Human genomic DNA was extracted from HeLa cells, digested with EcoRI, BamHI, XbaI, or HindIII, separated on a 0.8% agarose gel and transferred to GeneScreen nylon membranes (NEN Life Science Products). After UV cross-linking (Stratagene, San Diego, CA), the membrane was prehybridized with 100 µg/ml of denatured salmon sperm DNA (Promega Corp., Madison, WI) in 5× SSC, 0.5% SDS, 5× Denhardt's solution, and 0.1% sodium pyrophosphate at 65 °C in a roller hybridization oven (Hoefer Scientific, San Francisco, CA). Hybridization was carried out with gel-purified (GeneClean Bio101, Vista, CA), [32P]dCTP (Amersham Pharmacia Biotech) random-primed labeled (Boehringer Mannheim) 1.6-kb EPR-1 cDNA (13) for 16 h at 65 °C. After two washes in 2× SSC, 1% SDS for 30 min at 65 °C, and 0.2× SSC at 22 °C, radioactive bands were visualized by autoradiography using a Kodak X-Omat AR x-ray film and intensifying screens (DuPont). In other experiments, cultured lymphoblastoid cells were embedded in low melting preparative agarose (Bio-Rad) at the concentration of 2 × 106/220 µl block, and DNA was extracted by standard procedures. After block digestion with MluI or NotI, samples were separated by pulsed field gel electrophoresis on a 1% agarose gel for 20 h at 200 V with a pulse time of 75 s using a Bio-Rad CHEF DRII apparatus. After transfer to nylon membranes and UV cross-linking, hybridization with the EPR-1 cDNA and washes were carried out as described. In another series of experiments, a blot containing aliquots of genomic DNA isolated from several species (CLONTECH, San Francisco, CA) was hybridized with a 3' 548-nt fragment of the EPR-1 cDNA, as described above.
Northern Blots-- Multiple tissue blots of adult and fetal mRNA (CLONTECH) were prehybridized with 100 µg/ml of denatured salmon sperm DNA (Promega) and hybridized with an EPR-1-single strand-specific probe (see below) in 5× SSPE, 10× Denhardt's, 2% SDS, for 14 h at 60 °C. The membranes were washed twice in 2× SSC, 1% SDS for 30 min at 60 °C and once in 0.2× SSC at 22 °C before exposure for autoradiography. An EPR-1-specific single strand probe was generated by asymmetric polymerase chain reaction amplification of a 301-nt fragment of the EPR-1 cDNA generated by EcoRI (cloning site) and SacII digest and comprising the first 5' 226 nt of the EPR-1 coding sequence plus 75 nt of the retained regulatory intron (13). The gel-purified fragment was mixed with 15 pmol dNTP (New England Biolabs, Beverly, MA), 7.5 pmol of dCTP, and 25 µCi of [32P]dCTP (Amersham Pharmacia Biotech) in 20 mM Tris HCl, 50 mM KCl, pH 8.4, 1.5 mM MgCl2, plus 0.2 µg/µl of a SacII reverse EPR-1 primer 5'TGCTGGCCGCTCCTCCCTC3' and 2.5 units of Taq DNA polymerase (Life Science) in a total volume of 10 µl. 25 cycles of amplification were carried out with denaturation at 94 °C for 1 min, annealing at 52 °C for 1 min, and extension at 72 °C for 1 min. After centrifugation through a Sephadex G-50 spin column (Worthington Biochemical Corp., Freehold, NJ) at 14,000 × g for 5 min, the EPR-1 or Survivin probes were heated at 100 °C for 2 min and immediately added to the various hybridization reactions.
Transient Transfections of Antisense Constructs--
A control
antisense construct of intercellular adhesion molecule-1 was generated
by polymerase chain reaction amplification of the full-length
human intercellular adhesion molecule-1 cDNA (14) using
oligonucleotides 5'-GATCTAGACTCGCTATGGCTCCCAGC-3' and
5'-CCGCAAGCTTTCAGGGAGGCGTGGCTTG-3' containing
XbaI and HindIII restriction sites, respectively
(underlined sequences). The amplified product of 1605 nt was gel
purified and directionally cloned in pcDNA3 (Invitrogen, San Diego,
CA) for transfection in HeLa cells. A 708-nt
SmaI-EcoRI fragment of the EPR-1 cDNA (nt
379-1087) (13), potentially acting as a Survivin antisense, and a
sense-oriented Survivin construct (12) were also used for these
experiments. Subconfluent cultures of HeLa cells in 6-well tissue
culture plates were cotransfected with 1 µg of lacZ
reporter plasmid and 4 µg of the various sense- and
antisense-oriented constructs or the empty pcDNA3 vector using
LipofectAMINE (Life Technologies, Inc.). 48 h after transfection,
cells were fixed in 2% paraformaldehyde for 1 h and stained for
-galactosidase expression with 0.5 mg/ml 5-bromo-4-chloro-3-indolyl
-D-galactoside (Amersham Pharmacia Biotech), 5 mM potassium ferrocyanide, 5 mM potassium
ferricyanide, and 2 mM MgCl2 in
phosphate-buffered saline. The blue cells were counted and scored on an
inverted microscope. In another series of experiments, HeLa cells
(1 × 107) were transfected with 10 µg of control
pcDNA3 vector alone or the survivin antisense cDNA plus 50 µg
of salmon sperm DNA by electroporation (Gene Pulser, Bio-Rad) with a
single electric pulse at 350 V at 960 microfarads. 48 h after
transfection, HeLa cells were collected by trypsinization, pooled with
nonattached cells, and fixed in 70% ethanol on ice for 30 min. Fixed
cells were pelletted by centrifugation and suspended in 10 µg/ml
propidium iodide, 100 µg/ml RNase A, and 0.05% Triton X-100 in
phosphate-buffered saline, pH 7.4. After a 45-min incubation at
22 °C, samples were analyzed for DNA content by flow cytometry using
a FACScan (Becton Dickinson).
Generation of Inducible Survivin Antisense Transfectants-- The 708-nt SmaI-EcoRI fragment of the EPR-1 cDNA (see above) was directionally cloned in the sense orientation in the mammalian cell expression vector pML1 (a gift of Dr. R. Pytela, University of California, San Francisco). The vector is derived from the episomal mammalian expression vector pCEP4 by replacing the cytomegalovirus promoter cassette with the mMT1 promoter, directing Zn2+-dependent expression of recombinant proteins in mammalian cells (15). 10 million HeLa cells were transfected with 10 µg of control pcDNA3 vector or the Survivin antisense by electroporation as described above. 48 h after transfection, cells were diluted, plated onto 100-mm diameter tissue culture dishes, and selected for 4 weeks in complete growth medium containing 0.4 mg/ml hygromycin. Modulation of survivin expression in control cultures or Zn2+-induced antisense transfectants was carried by immunoblotting of detergent-solubilized cell extracts using 25 µg/ml aliquots of the affinity-purified antibody raised against the survivin sequence Ala3-Ile19, as described (12). In control experiments, Zn2+-induced vector control or survivin antisense transfectants were analyzed for modulation of Class I major histocompatibility complex by flow cytometry with monoclonal antibody W6/32.
Modulation of Apoptosis and Cell Growth in Inducible Survivin Antisense Transfectants-- Vector control or Survivin antisense transfectants were treated with 200 µM ZnSO4 in 0% fetal bovine serum for 24 h at 37 °C following by in situ determination of apoptosis by internucleosomal DNA fragmentation (TUNEL). Briefly, cells were harvested and centrifuged at 800 × g for 10 min at 4 °C, the pellet was fixed in 10% formalin overnight, dehydrated, and embedded in paraffin blocks, and sections of 3-5 µm were put on high adhesive slides. Samples were treated with 20 µg/ml proteinase K for 15 min at 22 °C, washed in distilled water, quenched of endogenous peroxidase in 2% H2O2 in phosphate-buffered saline, and subsequently mixed with digoxigenin-labeled dUTP in the presence of terminal deoxynucleotidyl transferase followed by peroxidase-conjugated anti-digoxigenin antibody. Nuclear staining in apoptotic cells was detected by 3', 3'-diaminobenzidine tetrahydrochloride dihydrate, according to the manufacturer's instructions (ApopTag, Oncor, Gaithersburg, MD). For control experiments, the enzyme incubation step was omitted. Morphologic features of apoptotic cells (apoptotic bodies) under the various conditions tested were also analyzed by hematoxylin/eosin staining. For proliferation experiments, vector control or Survivin antisense transfectants at 2 × 104/well were plated in 24-well tissue culture plates (Costar) and induced with 200 µM ZnSO4 in complete growth medium for 16 h at 37 °C, and cell proliferation was determined microscopically at 24 h intervals by direct cell count. Two independent clones of HeLa cell transfectants were used in these experiments with comparable results. In some experiments, analysis of DNA content in induced vector control or Survivin antisense transfectants in complete growth medium was carried out by propidium iodide staining and flow cytometry, as described above.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Identification of an EPR-1/Survivin Locus-- A digoxigenin-labeled P1 genomic clone (~100 kb) containing all four exons of the survivin gene (12) specifically labeled a single region on the long arm of a group E chromosome by fluorescence in situ hybridization (Fig. 1A). In two-color staining with probe D17Z1 specific for the centromere of chromosome 17, the Survivin P1 clone reacted with the long arm of chromosome 17 with band 17q25 (Fig. 1, A and B).
|
|
Differential Tissue Distribution of EPR-1 and Survivin Transcripts-- Consistent with the size of the spliced EPR-1 message (13), a single strand EPR-1-specific probe detected a prominent ~1.3-kb EPR-1 mRNA band in most adult and terminally differentiated human tissues (Fig. 3, upper panel). Strong EPR-1 expression was observed in human pancreas, skeletal muscle, heart, and various hematopoietic cell types, including peripheral blood leukocytes, lymph node, and spleen (Fig. 3, upper panel). Consistent with the reactivity of an anti-EPR-1 antibody with fetal tissues (16), a 1.3-kb EPR-1 mRNA was also found prominently in fetal kidney and liver and less abundantly in fetal lung and brain (Fig. 3, lower panel). Control hybridization with an actin probe confirmed comparable loading of mRNA in the various fetal samples (Fig. 3). In contrast, a Survivin-specific single strand probe did not react with mRNA isolated from normal adult tissues (12), whereas it detected a prominent ~1.9-kb transcript plus a fainter 3.4-kb species in various transformed cell lines (not shown) and in agreement with previous observations (12).
|
Effect of EPR-1 Expression on Apoptosis and Cell
Proliferation--
Transient co-transfection of HeLa cells with an
EPR-1 cDNA potentially acting as a Survivin antisense plus a
lacZ reporter plasmid produced significant loss of viability
in -galactosidase-expressing cells (Fig.
4). In contrast, co-transfection of
pcDNA3 vector alone, a sense-oriented Survivin construct, or a
control antisense of intercellular adhesion molecule-1 cDNA did not
affect HeLa cell viability under the same experimental conditions (Fig.
4). To determine more precisely the effect of regulated expression of
EPR-1 on Survivin inhibition of apoptosis, HeLa cells were stably
transfected with an EPR-1 cDNA under the control of an metallothionein-inducible promoter. In these experiments,
ZnSO4 induction of EPR-1 mRNA suppressed the expression
of endogenous Survivin, as determined by immunoblotting with an
anti-Survivin antibody (Fig.
5A). In contrast and
consistent with the expression of Survivin in transformed cell types, a
single 16.5-kDa Survivin band was immunoblotted in
metallothionein-induced HeLa cells transfected with the pML1 vector
alone (Fig. 5A). In control experiments, metallothionein
induction of EPR-1 mRNA did not affect the expression of Class I
major histocompatibility complex molecules in HeLa cell transfectants,
and no modulation of Survivin expression was observed in the absence of
ZnSO4 (not shown). Under these experimental conditions,
antisense down-regulation of Survivin resulted in massive apoptosis in
growth factor-deprived HeLa cells, as detected by in situ
internucleosomal DNA fragmentation by the TUNEL system (Fig.
5B, panel 1). Specific nuclear staining was
observed in 60-70% of metallothionein-induced, serum-starved HeLa
cell transfectants, whereas induced vector control cultures did not
stain with the digoxigenin-labeled dUTP probe (Fig. 5B,
panel 3). No staining was observed in the absence of
terminal deoxynucleotidyl transferase labeling (not shown).
Hematoxylin/eosin staining confirmed the presence of numerous apoptotic
bodies in ZnSO4-induced Survivin antisense transfectants,
as compared with vector control HeLa cells (Fig. 5B,
panels 2 and 4, arrowheads). The
effect of antisense down-regulation of Survivin on HeLa cell
proliferation was also investigated. As shown in Fig.
6A, suppression of endogenous
Survivin resulted in significant inhibition of cell proliferation, as
compared with induced vector control cultures (Fig. 6A).
3 days after metallothionein induction, the number of vector control
HeLa cell transfectants increased by 288% during optimal serum mitogen
stimulation, as opposed to a 20% increase in Survivin antisense
transfectants, under the same experimental conditions (Fig.
6A). The increased cell proliferation observed at later time
intervals (days 4-5) in induced antisense transfectants may reflect
heterogeneity in antisense expression with selective expansion of low
expressing cells (Fig. 6A). The potential ability of
Survivin to modulate apoptosis and cell proliferation under optimal
concentrations of serum mitogens was further investigated. Analysis of
DNA content in transiently transfected HeLa cells revealed a ~2-fold
increase in the fraction of apoptotic cells (sub-G1 peak)
in Survivin antisense transfectants as compared with vector control
cells, under the same experimental conditions (Fig. 6B,
M1 marker). This was also associated with a ~15-20%
decrease in the G2/M fraction in Survivin antisense
transfectants, as compared with vector control cultures (Fig.
6B, M4 marker). In stable HeLa cell
transfectants, zinc induction of Survivin antisense under optimal
growth conditions produced a ~1.4-fold increase in the
sub-G1 fraction and a ~20-36% reduction in the
G2/M peak, as compared with induced vector control cultures
(n = 2).
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In this study, we have shown that EPR-1 (13) and Survivin (12) are encoded by structurally and topographically distinct mRNA transcripts potentially originating from a gene cluster at 17q25. Secondly, constitutive or metallothionein induction of EPR-1, potentially acting as a Survivin antisense, down-regulated endogenous Survivin in transformed cells and resulted in increased apoptosis and inhibition of cell proliferation, even in the presence of optimal serum mitogen concentrations.
Among the regulators of programmed cell death (apoptosis), IAP proteins have recently attracted considerable attention for their ability to suppress an evolutionarily conserved step in apoptosis (4), potentially involving direct caspase inhibition (11). Deregulation of this pathway may also participate in human diseases, because inactivating mutations of neuronal apoptosis inhibitory protein contributed to spinal muscular atrophy (9), and this molecule was cytoprotective against cerebral ischemia in vivo (17). More recently, this paradigm has been extended to cancer, with the identification of Survivin as a structurally unique IAP protein selectively expressed during development and in all the most common human cancers but not in normal adult tissues in vivo (12). Intriguingly, the survivin gene was identified by hybridization with the EPR-1 cDNA, and its coding sequence was found to be extensively complementary to that of EPR-1 (12), suggesting the possibility of apoptosis regulation by a potential interaction between these two transcripts, i.e. natural antisense (18-21).
Here, Southern blots of human genomic DNA were consistent with the presence of multiple, evolutionarily conserved, EPR-1/Survivin-related genes, with several hybridizing fragments that could not be recapitulated by the complete physical map of 14,796 nt of the survivin gene (12). Despite this complex hybridization pattern, pulsed field gel electrophoresis and fluorescence in situ hybridization studies suggested the existence of a single EPR-1/Survivin locus spanning 75-130 kb on chromosome 17q25. Although mammalian genes transcribed in both directions have been described (22, 23), these data are more consistent with a model of separate genes encoding EPR-1 and Survivin, potentially arisen from duplication event(s) and clustered in relatively close proximity at 17q25 in a head-to-head configuration (24). The use of single strand-specific probes further demonstrated that EPR-1 and Survivin originated from two structurally different messages of 1.3 and 1.9 kb, respectively, expressed in a mutually exclusive fashion in adult and fetal tissues (12, 16). This is consistent with the heterogeneity of EPR-1 transcripts detected by conventional, double strand probes with hybridizing bands of 1.9, 3.4, and ~1.5 kb previously identified in EPR-1+ cells (25). Although it is currently not known if these two messages actually interact in vivo, we found that metallothionein induction of an EPR-1 mRNA suppressed the expression of endogenous Survivin in transfected cells. Consistent with the anti-apoptosis properties of Survivin (12), this resulted in increased apoptosis and significant inhibition of cell proliferation. Although accentuated by serum mitogen withdrawal, HeLa cell apoptosis following antisense down-regulation of Survivin was also observed under optimal growth conditions and was associated with a reduced number of proliferating cells in the G2/M fraction. In these experiments, the use of a noncoding EPR-1 cDNA potentially acting as a Survivin antisense ruled out the possibility that inhibition of Survivin was due to protein interactions. It is also unlikely that ZnSO4 induction of the metallothionein promoter may exert an independent anti-apoptotic function, because this has been attributed to ZnCl2, at concentrations 5-10-fold higher than those used here (26).
The findings described here may have profound implications for cancer therapy, where antisense-based strategies have been postulated for inhibition of several proto-oncogenes (27). Specifically, antisense blockade of anti-apoptotic bcl-2 decreased survival of leukemic cells in vitro (28), reduced tumorigenicity of lymphoma cells in athymic mice (29), and provided, at least in some cases, a positive therapeutic response in patients with non-Hodgkin's lymphoma (30). In this context and consistent with the data presented here, targeting Survivin may selectively increase the susceptibility of cancer cells to apoptosis-based treatment and reduce their overall growth potential. In addition to inhibiting cell viability pathways distinct and complementary with those of bcl-2 (11), suppression of Survivin by an endogenous EPR-1 transcript potentially acting as a natural antisense may overcome the drawbacks of limited specificity and insufficient delivery commonly observed with antisense oligonucleotides (27). Elucidation of the mechanisms regulating Survivin and EPR-1 gene expression should further facilitate the selective disruption of this novel anti-apoptosis pathway in cancer without affecting viability of normal tissues.
![]() |
ACKNOWLEDGEMENT |
---|
We thank Dr. Pytela for providing the pML1 vector.
![]() |
FOOTNOTES |
---|
* This work was supported by National Institutes of Health Grants HL43773 and HL54131 and was done during the tenure of an American Heart Association Established Investigatorship Award (to D. C. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Fellow of the Leukemia Research Foundation.
¶ To whom correspondence should be addressed: Yale University School of Medicine, BCMM 436B, 295 Congress Ave., New Haven, CT 06536. Tel.: 203-737-2869; Fax: 203-737-2290; E-mail: Dario.Altieri{at}yale.edu.
1 The abbreviations used are: EPR-1, effector cell protease receptor-1; kb, kilobase(s); nt, nucleotide(s).
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|